Veracyte, Inc

Veracyte, Inc specializes in molecular diagnostic assays, which analyze biological markers to guide clinical decisions. Their key devices include the C2inform test for cytogenetic analysis—used to detect chromosomal abnormalities in cytology samples—and the Prosigna Breast Cancer Prognostic Gene Signature Assay, which evaluates gene expression to assess breast cancer risk, recurrence likelihood, and potential response to therapy. These tools help clinicians tailor treatment plans based on molecular insights, improving patient outcomes.

Veracyte, Inc is headquartered in the United States, which means its devices are subject to FDA oversight for market authorization in the US. Internationally, the company’s Prosigna assay and other relevant devices are listed in the EU’s eudamed registry, reflecting compliance with EU IVD regulations. The US classification (Class A/IVD General) aligns with low-to-moderate risk devices, though specific regulatory pathways vary by jurisdiction.

Veracyte’s devices are listed in the EU’s eudamed registry, a transparent database for in vitro diagnostics under EU MDR. This listing confirms the company’s devices meet EU regulatory requirements for market placement, ensuring traceability and compliance for healthcare providers, distributors, and authorities. While eudamed is EU-focused, similar registries (e.g., FDA’s UDI database) apply in the US, though Veracyte’s devices are not explicitly listed there in the provided data.

Veracyte’s devices fall under Class A (general controls) and IVD General classifications. Class A typically covers low-risk devices with minimal direct patient interaction, while IVD General applies to in vitro diagnostics that pose moderate risk (e.g., gene expression assays). These classifications determine the regulatory scrutiny and post-market requirements, such as labeling standards or clinical performance data, though they do not imply approval—only that the devices meet specific regulatory criteria for their intended use.